Grants

2015 Grants

Brangman, Sharon; MD
Academic Title and Dept: Professor: Medicine; Div. Chief: Geriatrics, University Geriatricians, Alzheimer's Disease Assistance Center (ADAC)
Project Title: Legislative Grant - Elder Health Services
Granting Agency: NYS Department of Health
4/01/14-3/31/15
One Year: $41,666
Total Funding: $41,666

Endy, Timothy P.; MD, MPH
Academic Title and Dept: Professor: Medicine, Microbiology and Immunology, Public Health and Preventive Medicine, Division Chief: Infectious Disease
Project Title: Flavivirus Infections: Pathogenesis and Prevention
Granting Agency: University of Rhode Island
One Year: $117,136.00
Total Funding: $117,136.00

Gajra, Ajeet; MD, PI (institutional)
Celgene Protocol Number: ABI-007-NSCL-005 - Safety and Efficacy of nab®-paclitaxel (Abraxane®) in Combination with Carboplatin as First Line Treatment in Elderly Subjects with Advanced Non-small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Multicenter study.
12/14- 11/16

Gajra, Ajeet; MD, PI
Celgene Corp.
Safety and Efficacy of nab-Paclitaxel (Abraxane) in Combination with Carboplatin as First
Line Treatment in Elderly Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC): A
Phase IV, Randomized, Open-Label, Multicenter Study.
8/29/14-8/28/15
$7,350

Gentile, Teresa C.; MD, PhD, PI
Dana Farber Partners CancerCare Inc.
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Yrs.
12/19/14-12/18/15

Gentile, Teresa C.; MD, PhD,
TG Therapeutics Inc.
A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
3/11/2015-3/10/2020

Graziano, Stephen; MD, PI
Heat Biologics, Inc.
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS-110) in Combination with Low Dose (Metronomic
Cyclophosphamide Followed by Sequential Chemotherapy vs. Chemotherapy Alone in patients with Non-small Cell Lung Adenocarcinoma after Failure of Two Previous Treatment Regimens for Advanced Disease.
1/29/15-1/28/16

Holz, Dr. George G; PhD
Academic Title and Dept: Professor: Medicine, Pharmacology
Project Title: Molecular Basis of
Antidiabetogenic Hormone Action
Granting Agency: National Inst of Diabetes Digestive Kidney Disease
One Year: $434,462.00
Total Funding:$ 1,743,694.00

Lappin, Sarah; DO, PI
Lown Institute
RightCare Young Innovator Grant
Learning to Talk: Overuse; An Inter- Professionalism Communications Curriculum Focused on the Nexus of Overuse and Patient- Centered Care.
11/01/14-10/31/15
$7,350

Pan, Dorothy C.; MD, PI
Infinity Pharmaceuticals, Inc.
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination with Rituximab vs Rituximab in Subjects with Previously-Treated Follicular Lymphoma.
12/12/14-12/11/15

Weinstock, Ruth; MD, PHD, PI
Mylan Inc.
An Open-Label, Randomized, Multi-Center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine with Lantus in Type 1 Diabetes Patients.
10/30/14-10/29/15

Weinstock, Ruth; MD, PhD
Academic Title and Dept: Distinguished Service Professor of Medicine, Research Professor of Neuroscience and Physiology, Div. Chief: Endocrinology, Diabetes and Metabolism
Project Title Continuous Monitoring of Glycemic Oscillations in Interstitial Fluid
Granting Agency: Ultradian Diagnostics LLC
9/01/14-8/31/15
One Year: $196,798
Total Funding: $196,798

Weinstock, Ruth; MD, PHD, PI
Jaeb Center for Health Research Inc.
Racial Differences in Mean CGM Glucose in Relation to HbA1c.
10/01/14-9/30/15
$39,600

Seth, Rahul,; DO,
OncoMed Pharmaceuticals Inc.
A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane Plus Placebo versus Gemcitabine, Abraxane plus 1 or 2 Truncated Courses of Demcizumab in Subjects with 1st-line Locally Advanced or Metastatic Pancreatic Cancer
1/9/2014-1/1/2015

Seth, Rahul; DO, PI
Prometheus Laboratories, Inc.
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.
1/19/15-1/18/16

Seth, Rahul; DO, PI
Merck Sharp and Dohme Corp.
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) vs. Paclitaxel, Docataxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer.
12/15/14-12/14/15

Stewart, Anna M.; PhD, MPA, PI
Syracuse University
Linking Vector Dispersal and Remotely Sensed Breeding Sites to Generate High Resolution Risk Maps of Malaria Transmission.
1/1/15-6/30/15
$1,700

Perl, Andras; MD, PhD
Academic Title and Dept: Professor of: Medicine, Biochemistry and Molecular Biology, Microbiology and Immunology, Div. Chief: Rheumatology, Co-Director: MD/PhD Program
Project Title: Metabolic Control of T-cell Lineage Specification in SLE Granting Agency: National Institute of Allergy & Infectious Disease
2/1/15-1/31/16
One Year: $402,500
Total Funding: $2,021,458

Perl, Andras; MD, PhD, PI
Rheumatology Research Foundation Health Professional Research Preceptorship.
9/01/14-8/31/15
$2,000

Poiesz, Bernard; MD, PI
Avillion Development 1 Ltd
A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.
9/25/14-9/24/15

Poiesz, Bernard;  MD,
Cerulean Pharma Inc.
A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination with Bevacizumab in Patients with Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)
2/12/2015-2/11/2016